Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Henry Schein beats quarterly profit estimates on strong dental, medical equipment sales February 24, 20261:40 PM UTCUpdated ago By Reuters Feb 24 (Reuters) - Henry Schein (HSIC.O), opens new tab on Tuesday beat fourth-quarter profit estimates and forecast annual profit largely in line with Wall Street expectations on the back of stabilizing demand for its dental and medical equipment. After a ...

MiniMed announces launch of IPO roadshow [Accessibility Statement] Skip NavigationGALWAY, Ireland, Feb. 24, 2026 /PRNewswire/ -- MiniMed Group, Inc. (MiniMed), a subsidiary of Medtronic plc (Medtronic) (NYSE: MDT), today announced that it has launched a roadshow for the initial public offering (IPO) of 28,000,000 shares of its common stock. The proposed offering is part of Medtronic's previously announced plan to separate its Diabetes business into an independent public company.The IPO price is currently ex ...

Haemonetics Receives FDA Clearance for NexSys® PCS Plasma Collection System with Persona® PLUS Technology [Accessibility Statement] Skip Navigation--BOSTON, Feb. 23, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative solutions designed to improve patient outcomes, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the NexSys PCS® Plasma Collection System with Persona® PLUS technology. Persona PLUS represent ...

InMode Announces Conclusion of Independent Transaction Committee Review [Accessibility Statement] Skip NavigationYOKNEAM, Israel, Feb. 23, 2026 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) a leading global provider of innovative medical technologies ("InMode" or the "Company"), today announced that the independent transaction committee of its Board of Directors (the "Committee") has completed its review of proposals received in connection with a potential transaction.Since its formation, the Committee has con ...

Core Insights - BD has launched the BD Vacutainer® Urine Complete Cup Kit, a three-tube collection system aimed at enhancing diagnostic accuracy and efficiency in urine testing [1] - The kit is designed to preserve specimen quality, streamline testing processes, and reduce the need for repeat collections, thereby improving patient care [1] Product Features - The kit includes a castile wipe for patient preparation, a discard tube with no additives, a tube for urinalysis testing, and a tube for culture and sensitivity testing [1] - It features a sterile urine cup and lid with an integrated transfer device, compatible with a wide range of diagnostic equipment [1] Clinical Impact - Urine testing is essential for diagnosing various conditions, and contaminated specimens can lead to inappropriate treatments; a study indicated that nearly 44% of patients with contaminated urine cultures received incorrect antibiotic therapy [1] - Closed-system solutions like the BD Vacutainer® Urine Collection portfolio help minimize contamination risks and enhance overall efficiency in urine specimen management [1] Company Overview - BD is one of the largest pure-play medical technology companies globally, focusing on advancing health through innovation in medical essentials, connected care, biopharma systems, and interventional solutions [1] - The company employs over 60,000 individuals and delivers billions of products annually, positively impacting global healthcare [1]

Company Overview - ResMed is a medical equipment company based in San Diego, California, originally founded in Australia, specializing in cloud-connectable CPAP machines for obstructive sleep apnea treatment [1] - The company has over 10,000 employees and operates in more than 140 countries, with two primary business units: Sleep and Respiratory Care, and Software as a Service (SaaS) [2] Product and Service Offering - The Sleep and Respiratory Care unit provides industry-leading CPAP machines for various patient needs, from those requiring therapy at night to those needing life-support ventilation [2] - The SaaS unit offers software for durable or home medical equipment, facilitating out-of-hospital care [2][3] Financial Performance - ResMed reported an annual revenue of $4,685 million, with a compound annual growth rate (CAGR) of 13.6% over the last three years [5] - The latest reported gross margin for ResMed was 57.4%, indicating strong profitability from core products and services [6] - The company reported a profit of $1,021 million in the last financial year, reflecting a CAGR of 29.1% compared to three years ago when the profit was $475 million [7] Financial Health - ResMed's current net debt is -$624 million, indicating that the company has more cash than debt, which can be seen as a safety buffer [9] - The debt/equity ratio stands at 18.0%, suggesting that ResMed has more equity than debt, indicating lower leverage [10] - The return on equity (ROE) for ResMed was 22.7% in FY24, demonstrating efficient capital allocation and value generation [11] Valuation Insights - ResMed shares currently have a price-to-sales ratio of 5.38x, below the 5-year average of 8.70x, suggesting that shares are trading at a lower valuation compared to historical averages [12]

Haemonetics to Present at Raymond James 47th Annual Institutional Investors Conference [Accessibility Statement] Skip Navigation--BOSTON, Feb. 20, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 47th Annual Institutional Investors Conference on Monday, March 2, 2026 at 10:25 a.m. ET.The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website ...

FDA Approves MRI TechnologyThe FDA has recently approved GE HealthCare’s next-generation SIGNA MRI technology, which is designed to enhance precision imaging and clinical efficiency. This milestone is significant as it includes the SIGNA Sprint with Freelium technology, aiming to reduce helium dependency—a critical advancement in making MRI technology more sustainable and cost-effective.The new SIGNA Bolt 3T MRI scanner, part of this FDA clearance, is noted for its powerful performance and sustainable desig ...

Key Takeaways AMN reported Q4 EPS of 22 cents, down 70.7%, while revenues rose 1.8% year over year.Nurse and Allied Solutions' revenues rose 8%, aided by $124M in labor disruption events.AMN expects Q1 2026 revenues of $1.225B-$1.240B, up 78%-80% from last year.AMN Healthcare Services, Inc. (AMN) delivered adjusted earnings per share (EPS) of 22 cents in the fourth quarter of 2025, which declined 70.7% year over year. The figure was in line with the Zacks Consensus Estimate.GAAP loss per share for the quart ...

Baird Medical to Showcase Minimally Invasive Thyroid Solutions at Upcoming US Clinical Conferences [Accessibility Statement] Skip NavigationNEW YORK, Feb. 19, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation for three major clinical conferences this quarter. These events are pivotal to the company's expansion, providing U.S. clinicians dir ...